The advent of COVID-19 and the fast-tracked vaccine to prevent it has everyone talking. It is exciting when a vaccination can be developed, tested and produced at the pace at which the COVID-19 vaccine was generated. The world was waiting and the pharmaceutical industry answered. The question remains: what really is entailed in bringing a new vaccine to market and manufacturing enough supply for the whole world in a matter of months?
Professor Emadi’s course, Bio-Manufacturing: Pharmaceutical Processes, helps answer some of those questions and will serve as a foundational course in the engineering of these manufacturing processes for students who now may be considering the rapidly growing pharmaceutical manufacturing industry.
This compelling course, which is offered in Spring 2021, will give students a background in the fundamentals of biology and chemistry in engineering, allow them to examine case studies in pharmaceutical and vaccine manufacturing, and gain an understanding of key phrases in the process of drug manufacturing from bench to bottle.
Students will also learn the difference between conventional and biologics drugs, and gain an understanding of bioprocessing and bio-manufacturing as well as the main technologies used in the biopharmaceutical industry.
Students will gain:
- fundamentals of biology and chemistry in engineering
- examine case studies in pharmaceutical and vaccine manufacturing
- understand key phrases in the process of drug manufacturing from bench to bottle
- differentiate between conventional and biologics drugs
- understand bioprocessing and bio-manufacturing, and technologies used in the industry
Bio-Manufacturing: Pharmaceutical Processes, is listed under the course numbers MEM 3295 and BME 4985 and will be offered Tuesday/Thursday at 12:30-1:45 PM. Students who are interested in bio-manufacturing, pharmaceuticals, and those who want to gain more experience with biology and chemistry for engineering are encouraged to enroll.
Professor Emadi’s current focus is molecular, biochemical, and cell biology with an emphasis on the application and development of antibody phage display, protein engineering and cell-based assay. Her past work includes the bio production, the purification and the characterization of self-assembling peptide nanoparticles (SAPNs) as a novel immunogenic design of the Malaria and Influenza vaccine; the development of recombinant antibodies for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s; the mechanisms of megakaryocytopoiesis dysregulation in myeloproliferative syndrome. She is an Assistant Professor in Residence with the Biomedical Engineering Department and also teaches with the Management and Engineering for Manufacturing (MEM) program.